QuartzBio secures growth investment from Eir Partners to advance AI‑driven clinical trial intelligence, improving efficiency, data integrity, and outcomes for biopharma. New capital fuels product enhancements as leading biopharma adopt QuartzBio to eliminate operational inefficiencies and protect trial outcomes.
Visit QuartzBio at Bio‑IT World 2026 to see interoperable AI agents unify biomarker, sample, and clinical data. Cut data wrangling by 90% and deliver insights 10× faster.
Tune in to learn how QuartzBio’s Precision Medicine agentic framework, powered by proactive and prescriptive AI, is shortening trial timelines, improving regulatory adherence, and driving operational excellence across the R&D value chain. Our Sample Intelligence AI Agents monitor samples, detect emerging issues, automatically flag root causes, and deliver actionable, corrective guidance.
This week, as part of our v13.0.0 major release, our customers gained access to the expanding QuartzBio Learning Lab – a centralized, easy-to-navigate hub for training, product documentation, and updates.
Read this 1-page info sheet highlighting a case study showing how QuartzBio delivers 10x faster insights, enabling quicker study closures and better data quality — with no added headcount required.
Request our white paper to see our breakdown of the costs associated with achieving and maintaining compliance using traditional processes and point solutions. You’ll also learn how QuartzBio’s platform approach transforms compliance processes, helping customers lower costs immediately, reducing compliance issues and data problems by over 80%.
Learn more about the release of version 12.0.0 of QuartzBio’s Precision Medicine AI Agent Platform, featuring enhancements to our Sample Intelligence Solution, our Biomarker Intelligence Solution, and improvements to the underlying data management layer. New capabilities include large file support, dynamic analytics, and richer clinical insights.
The new ICH E6(R3) GCP guideline, impacting clinical studies starting 23 July 2025, introduces significantly more detailed requirements around the integrity and governance of data assets and trial records, including biospecimens, their derivatives, and all associated clinical and assay data generated during trials. To help precision medicine teams ensure they meet these new requirements, we have developed this compliance checklist.
This month, we released version 11.0.0 of QuartzBio’s Precision Medicine AI Agent Platform, featuring enhancements to our Sample Intelligence Solution, our Biomarker Intelligence Solution, and performance improvements to our data management layer.
I just read Microsoft’s latest Work Trend Index report, “The Year the Frontier Firm Is Born,” and it resonates deeply with the challenges and opportunities we’re seeing in precision medicine R&D. Read about QuartzBio’s approach and find links to additional resources on deploying precision medicine AI agents.
QuartzBio is the only company purpose-built to deliver end-to-end Sample and Biomarker Intelligence for clinical-stage biopharma teams. Powered by a network of domain-specific AI agents, our solutions transform fragmented data into actionable intelligence, enabling conversational insights into your unified ecosystem of sample, clinical, and biomarker data.
QUARTZBIO® is a registered trademark of Precision Regulatory and Translational Sciences, Inc., dba QuartzBio, in the United States and/or other jurisdictions. All rights reserved.
© 2026 QuartzBio.
All rights reserved.
Privacy Policy | GDPR
